A vocal advocate for science integrity and reproducibility believes Pfizer’s recent call to retract five cancer research papers should be commended even as the field struggles with irreproducible science. At the same time, it points to the continued need to improve research oversight.
C. Glenn Begley, former head of oncology and hematology research at Amgen, believes this latest example of flawed research is just the tip of the iceberg — not for industry specifically, but for all published science.
“These retractions appear to be intentional image duplication, but there’s an entire spectrum of flawed research published in journals at every tier,” Begley said in an interview last week.
